文献速递胃肠外科围术期管理与 ERAS

食管癌多模式治疗前无需预置肠内营养通路

Preoperative enteral access is not necessary prior to multimodality treatment of esophageal cancer.
PubMed 文献 · Surgery · 2017-12-01

该回顾性研究纳入156例食管癌切除术患者,其中99例接受新辅助放化疗。比较新辅助放化疗前放置肠内营养通路(50例)与食管切除术中放置(49例)的患者,发现两组吞咽困难比例、血清白蛋白、围手术期体重下降及并发症发生率均无显著差异,提示新辅助治疗前预置肠内营养通路无营养或围手术期获益。

要点

  • 新辅助放化疗前预置肠内营养通路与术中放置相比,围手术期体重下降和并发症无差异。
  • 吞咽困难不应作为常规预置肠内营养通路的依据。
  • 肠内营养通路可留待 definitive 切除术中放置或仅用于内镜下明确梗阻者。

核心结论

  • 食管癌新辅助放化疗前放置肠内营养通路未显示营养或围手术期获益。

研究设计与样本

  • 回顾性研究,2007至2014年接受食管切除术的食管恶性肿瘤患者156例,其中99例接受新辅助放化疗并纳入研究队列。

临床怎么用

  • 食管癌患者可直接接受新辅助放化疗及手术,肠内营养通路可在 definitive 切除术中放置。
  • 肠内营养通路可保留给内镜下明确梗阻的患者。

局限性

  • 回顾性研究设计。
  • 样本量有限(共99例)。
  • 存在医疗提供者偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Surgical enteral access prior to multimodality treatment for esophageal cancer is controversial as dysphagia is often used for feeding tube referral. We hypothesized that enteral access before neoadjuvant chemoradiation for esophageal cancer provides no benefit compared to that placed during definitive esophagectomy. METHODS: Patients undergoing esophagectomy for esophageal malignancy from 2007 - 2014 were retrospectively identified. Clinicopathologic factors were recorded including preoperative enteral access, weight change, nutritional laboratory works, and perioperative complications. RESULTS: Of 156 identified patients, 99 (63.5%) received neoadjuvant chemoradiation and comprised the study cohort. Fifty (50.5%) underwent enteral access (gastrostomy [14], jejunostomy [32], other [4]; "Access Group") prior to chemoradiation followed by esophagectomy and were compared to 49 "No-Access" patients who underwent enteral access during esophagectomy. Clinicopathologic variables were similar between cohorts. The Access and No-Access cohorts had similar reported dysphagia (86% vs 75.5%, respectively; P = .2) and mean preesophagectomy serum albumin (3.9 vs 4 gm/dL, respectively; P = .2). Weight loss ± 6-month periesophagectomy was similar between access versus No-Access cohorts (-11.2% vs -15.4%, respectively; P = .1). Weight loss during this period was likewise similar for patients with dysphagia in the Access (-11%) versus No-Access group (-15.2%, P = .1). No difference in complication rates was noted between Access (64%) and No-Access groups (51%, P = .2). CONCLUSION: Despite healthcare provider bias, there seems to be no nutritional or perioperative benefit for enteral access before neoadjuvant chemoradiation for esophageal malignancy. Patients with esophageal malignancy should therefore proceed to appropriate neoadjuvant and surgical therapy with enteral access performed during definitive resection or reserved for those with frank obstruction on endoscopy.

来源:Surgery,查看原文。版权归原作者所有。

引用

  1. Jenkins TK, Lopez AN, Sarosi GA, et al. Preoperative enteral access is not necessary prior to multimodality treatment of esophageal cancer. Surgery. 2017. PMID: 29198770. doi:10.1016/j.surg.2017.09.046

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。